



Docket Numbers
20080111 and 20040316

Method and Composition of treating dyshidrosis(pompholyx) and related dry skin disorders

Patent No. 7,357,950 and 7,666,451

A topical formulation and method of use effective in establishing remission of severe dyshidrosis, non-responsive to current prescription medicines and OTC triple antibiotics, lotions or skin products.

Florida A&M University Division of Research

Contact:

Rose Glee, Ph.D.
Director
Office of Technology
Transfer, Licensing &
Commercialization
660 Ardelia Court
Tallahassee, FL-32307
Phone: 850-412-7232
rose.glee@famu.edu

Inventors:

Karam Soliman, Ph.D.
Karam.soliman@famu.edu
Elizabeth Mazzio, Ph.D.

Key Features:

All Natural – Use of combined oral nutritional applications for the skin in combination with topical effective ointments to treat conditions non responsive to topical steroids.

Field:

Pharmaceutical

Technology:

Skin and Nutritional.

Stage of Development:

Early startup: ready for market and commercialization

Status:

Seeking further research & development support and/or licensing partner.

Patent(s) Status:

Issued

Background:

Hand eczema is a widespread skin disorder, encompassing a variety of diseases such as contact dermatitis and dyshidrosis (pompholyx). Dyshidrosis itself is characterized by initial onset of blistering and dry cracked skin on the hands or feet, affecting the tips and sides of fingers, toes, soles and palms. The disease develops progressively to occupy larger surface area and extensive pathological skin scaling, peeling, bleeding, deep fissures and open wounds that in many cases do not heal. There is very little known about the disease, other than a wide held believe it is due to stress, anxiety or contact with some form of irritant or allergen.

Statement of Problem:

While topical steroidal or non-steroidal immuno-suppressive agents remain the primary treatment for dyshidrosis, atopic dermatitis and psoriasis, they don't address the etiology of the disease , in some cases are not effective or only a temporary solution, and are known to lead to local and systemic side effects with extended use. Skin conditions non-responsive to topical steroidal creams render chronic long-term afflictions affecting quality of life. For the case of dyshidrosis, confinement to white gloves, a potential loss of functional utility of the hands and/or feet and avoiding direct contact with ubiquitous substances such as soap, water and detergents.

Potential Solution:

FAMU has developed and patented an inside (oral nutritional) – outside (topical) product for deep skin care originally designed for dyshidrosis. The principles governing development of the topical/oral product combination include capacity to [1] augment circulation or blood flow to hands and feet [2] provide potent anti-microbial: anti-parasitic, anti-bacterial, anti-protozoal, anti-fungal and anti-viral properties to destroy growth of invading pathogenic organisms or unknown retroviruses [3] dermal anti-inflammatory agents [4] cutaneous vasodilators [5] aloe vera and [6] contain constituents that destroy or remove dead skin, which correlate with healing.

Commercialization Status:

The herbaceutix™ Inside (Nutritional Supplement) - Outside (Cream) Skin Care product line is currently in the early development stage but product is market ready. The herbal extract formulations are safe, complete, and prototypes can be manufactured on a small scale. We are seeking collaborative partners or licensees in the Nutraceutical and/or HealthCare or Topical Skin Care Industries to take these developments into commercialization. The target market of this product is unique as it will not be an anti-aging, moisturizing cream, but rather for adverse skin conditions that affect quality of life.